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ABSTRACT
A simple and rapid liquid chromatographic method is presented for the determination of morphine HCl, ketamine HCl and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride (PVC) infusion bags. Assay was performed on a pre-packed HPLC
Hypersil BDS C18 3.9 mm × 15 cm, particle size 3 µm column under controlled ambient temperature. Separation among morphine
HCl, ketamine HCl, droperidol and their associated degradation compounds was achieved by isocratic elution using mobile phase consisting of methanol/acetonitrile/0.01 M 1-octane sulfonic acid sodium in 0.005 M phosphate buffer (pH 4.0) (50/50/100) at a flow rate
of 1.0 ml/min. An UV/VIS variable programmable wavelength detector set at 254 nm was used. Sample volumes of 20 µL were
injected. There was no need for sample pre-treatment.
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INTRODUCTION
Morphine HCl is a potent opioid analgesic(1). On the
other hand, droperidol is a potent butyrophenone neuroleptic that is commonly used with fentanyl citrate in combination product to effect neuroleptananalgesia(2). Ketamine
HCl is used as an anesthestic for diagnostic or short
surgical operations(3). A solution of 1.0 mg/mL morphine
HCl, 1.0 mg/mL ketamine HCl and 21.4 µg/mL droperidol
in 0.9% sodium chloride is commonly used in the treatment
of cancer patients. Individual analyses of morphine HCl,
ketamine HCl and droperidol have been performed utilizing
titration(4), spectrophotometry(5) and HPLC(6~12). However,
a single method for the simultaneous determination of these
three active ingredients in 0.9% sodium chloride is still
lacking. The objective of this study was to develop a rapid
and precise stability-indicating HPLC method for the simultaneous determinations of morphine HCl, ketamine HCl and
droperidol in 0.9% sodium chloride solution.

MATERIALS AND METHODS

David, USA (lot ZH708); droperidol (Dehyobenzperidol®),
2.5 mg/mL, 10 mL, Janssen Pharmaceutic, USA (lot
00EB314); 0.9% sodium chloride injection, 100 mL,Y. H.
Pharma., Taiwan, ROC (lot 107A01E). The primary reference standard of ketamine HCl (lot 788003) was a gift from
Pake-David Pharmapeutic, Australia. The primary reference
standard of morphine HCl (NM410-871001) was from
National Bureau of Controlled Drugs, Executive Yuan,
Taiwan, ROC and droperidol (lot 9013-1) was provided by
Jannsen Pharmaceutic, USA. 1-Octane sulfonic acid sodium
was from Fisher Scientific, loughborough Leics, LE11, SRG
UK (lot 9930226 080). Methanol and acetonitrile (HPLC
grade) were purchased from E. Merck, Germany.
II. Apparatus
A reverse-phase high-performance liquid chromatograph (Shimadzu, Japan) equipped with a Hypersil C18
column (3.9 mm i.d. × 15 cm, 3 µ m, Japan), an UV
detector and a recording digital integrator (C-R6A,
Shimadzu, Japan) was used. The UV detector was set at
254 nm, and the recorder was set at 1.0 cm/min.

I. Materials

III. Mobile Phase

The following injection solutions were used: morphine
HCl injection, 10 mg/mL, 1.0 mL, National Bureau of
Controlled Drugs, Executive Yuan, Taiwan, ROC (lot
890816); ketamine HCl (Ketalar®), 50 mg/mL, 10 mL. Pake-

The mobile phase was made of methanol/acetonitrile/0.01 M 1-octane sulfonic acid sodium in 0.005 M
phosphate buffer (pH 4.0) (50/50/100). The mobile phase
was prepared fresh daily and degassed by a water aspirator
immediately prior to use. The flow rate of 1.0 mL/min was
used.
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RESULTS AND DISCUSSION

IV. Working Standard Solutions of Calibration Curve
The stock solution was prepared by dissolving 100 mg
of morphine HCl, 100 mg of ketamine HCl and 10 mg of
droperidol in 0.9% sodium chloride in a 10 mL calibrated
volumetric flask and diluting to volume with the mobile
phase. Aliquots of 0.5, 1.0, 2.0, and 3.0 mL of the stock
standard solution were accurately pipetted into 25 mL calibrated volumetric flasks and diluted to volume with the
mobile phase. The solutions were prepared fresh daily for
establishing a standard curve.
V. Validation of the HPLC Method
A stock solution of morphine HCl admixture was
prepared with a concentration of approximately 1.0 mg/mL
morphine HCl, 1.0 mg/mL ketamine HCl and 21.4 µg/mL
droperidol. Four standard solutions ranging from 0.2-1.2
mg/mL morphine HCl, 0.2-1.2 mg/mL ketamine HCl and
20-120 µ g/mL droperidol were prepared by volumetric
dilution with mobile phase. Each standard solution was
assayed three times. Calibration curves for the mean (SD)
active ingredient peak heights against original active ingredient concentrations were constructed. Linear regression
analysis was performed to calculate the regression equation
and the limit of detection (LOD) from

I. High Performance Liquid Chromatography (HPLC)
Assay
The HPLC method developed in this study provides
excellent simultaneous separation and quantitation of
morphine HCl, ketamine HCl and droperidol. The stabilityindicating nature of the assay was demonstrated in the chromatograms obtained from solutions forcibly degraded by
temperature with either 0.1 mL of 6 N sodium hydroxide
adjusted to pH 12 at 60˚C for 6 hr, 0.1 mL of 6N
hydrochloric acid adjusted to pH 2 at 60˚C for 6 hr, or 3%
hydrogen peroxide at 60˚C for 6 hr, respectively.
Reduction in the component peak heights was noted in the
chromatograms (Figure 1). The purity of the chromatographic peaks of interest was confirmed by using a photodiode array detector within the wavelength range of 192-360
nm. The relative retention times for morphine HCl,
ketamine HCl and droperidol were 6.9, 10.1 and 14.2 min,
respectively. The HPLC analytical parameters are listed in
Table 1. The HPLC assay showed good separation of the
peaks of morphine HCl, ketamine HCl, droperidol and
other apparent degradation products (Figure 1) and is
indicative of the stability.
II. Calibration Curves and Reproducibility

(I)

VI. Determination of Morphine HCl, Ketamine HCl and
Droperidol in Admixture Injection
The mobile phase was pumped through a C18 column
that was set at a flow rate of 1.0 mL/min at room temperature. The analytical procedure was initiated after a stable
baseline was achieved when the working standard solution
was injected. Standard working solutions containing 1.0
mg/mL morphine HCl, 1.0 mg/mL ketamine HCl and 21.4
µg/mL droperidol were injected into to obtain calibration
curves. Before running the sample, the percentage recovery
of morphine HCl, ketamine HCl and droperidol in the
sample solution using the HPLC method might be obtained
either by the calibration curve method or by calculations
using equation (II) (the mass of sample taken is assumed to
be the same as the mass of standard morphine HCl,
ketamine HCl and droperidol in a specific working standard
solution).
Recovery (%) = Dsample/Dstandard × 100%

(II)

The calibration curves of morphine HCl, ketamine HCl
and droperidol were established by plotting the peak
heights of each active ingredient against its associated concentrations. The concentration used for each drug was 0.21.2 mg/mL for morphine HCl, 0.2-1.2 mg/mL for ketamine
HCl and 20-120 µg/mL for droperidol. A statistical linear
regression was performed for each agent using concentra-
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Where Dsample is the peak height of morphine HCL,
ketamine HCl or droperidol in the sample solution, and
Dstandard is the peak height of morphine HCl, ketamine HCl
or droperidol in the working standard solution.
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Where SD was the standard derivation of the Yintercept and S was the slope of the calibration curve.
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LOD = 3.3 SD/S
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Figure 1. Chromatograms of morphine HCl, ketamine HCl and
droperidol as (A) freshly prepared and (B) after exposure to a strong
base and beat. Peak 1: morphine HCl; peak 2: ketamine HCl; peak 3:
droperidol; peak 4: unidentified degradation products.
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Table 1. The HPLC parameters for the determination of morphine
HCl, ketamine-HCl and droperidol
Morphine
Ketamine
Droperidol
K’ (capacity factor)
0.44
1.18
3.67
α (selectivity)
2.68
3.11
As (asymmetry factor)
1.0
1.0
1.0
Rs (resolution)
6.0
13.3
N (plate number)
1024/15 cm 1600/15 cm
1806/15 cm
k = (Ti-Tm)/Tm, αxy=k’y/k’x, αyz=k’z/k’y
k’x: capacity factor of morphine; k’y: capacity factor of ketamine; and
k’z: capacity factor of dropendol.
As: as defined in the USP XXII.
Rsxy = (Tiy – Tix)/(1/2Wx + 1/2Wy); Rsyz = (Tiz – Tiy)/(1/2Wz +
1/2Wy)
Ti: retention time of active ingredient; Tm: retention time of mobile
phase; Rsxy: resolution value of morphine HCl and ketamine HCl;
Rsyz: resolution value of morphine HCl and droperidol. Tix: retention
time of morphine HCl peak; Tiy: retention time of ketamine HCl
peak; Tiz: retention time droperidol peak. 1/2Wx: half wave width of
morphine HCl peak; 1/2Wy: half wave width of ketamine HCl peak;
1/2Wz: half wave width of droperidol peak
N = 16 (Ti/wi)2, wave width of each compound peak.

Table 2. Assay of morphine HCl, ketamine HCl and droperidol injections
Preparation
Labelled amount
% Recoverya
(mg/mL)
Mean
SD
CV
Ab
10
103.2
1.16
1.12
50
101.4
1.34
1.32
Bc
2.5
101.0
0.50
0.50
Cd
D+e contains
Morphine HCl
1.0
103.2
1.38
1.34
Ketamine HCl
1.0
101.9
1.66
1.63
Droperidol
0.0241
101.1
0.25
0.25
a
Results of three replicate determinations: SD = standard deviation;
CV = coefficient of variation.
b
10 mL of Morphine HCl injection, 10 mg/mL, National Bureau of
Controlled Drugs, Executive Yuan, Taiwan, ROC (lot 890805).
c
Ketalar®, 50mg/mL, 10 mL. pake-David, USA (lot ZH708).
d
10 mL of Dehyobenzperidol®, 2.5 mg/mL, Janssen Pharmaceutic,
USA, (lot EB314).
e
I.V. admixtures of morphine HCl, ketamine HCl and droperidol in
0.9% sodium chloride were prepared by commercially available
products.

tion against peak height. Three regression lines (Y = aX +
b; Y = peak height, X = concentration) were obtained for
morphine HCl, a = 6.5343 ± 0.004199, b = 0.02957 ±
0.001151, r = 0.9999; for ketamine HCl, a = 1.0924 ±
0.001019, b = 0.01387 ± 0.0000864, r = 0.9995; for
droperidol, a = 1.1624 ± 0.006223, b = 0.04914 ±
0.0006946, r = 0.9999. The limit of detection (LOD) for
morphine HCl, ketamine HCl and droperidol were 15.73
µ g/mL, 0.2610 µ g/mL and 1.802 µ g/mL, respectively.
Inter-day and intra-day variations for morphine HCl,
ketamine HCl and droperidol in the same concentration
ranges were determined to be 2.25%, 2.33%, 3.42% and
3.66%, 2.12% and 3.08%, respectivity. The utility of the
method commercially available injections (Table 2).
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CONCLUSIONS
This study successfully concluded the development of
a HPLC method to simultaneously determine the concentrations of morphine HCl, ketamine HCl and droperidol from
their I.V. admixtures in 0.9% sodium chloride solution.
This method is simple, rapid, precise and indicative of the
stability.
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